This player's pipeline should keep growth going over the long run.

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, ...

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug applications process ...

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...

For most students, science is limited to the lab bench — pipetting solutions and taking precise measurements to check the ...

Vertex has the revenue power to excel during any market environment.